Compare DV & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DV | TRVI |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2021 | 2019 |
| Metric | DV | TRVI |
|---|---|---|
| Price | $10.83 | $14.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $16.37 | ★ $21.55 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $748,291,000.00 | N/A |
| Revenue This Year | $12.68 | N/A |
| Revenue Next Year | $9.75 | N/A |
| P/E Ratio | $272.13 | ★ N/A |
| Revenue Growth | ★ 13.92 | N/A |
| 52 Week Low | $7.61 | $5.38 |
| 52 Week High | $16.82 | $16.12 |
| Indicator | DV | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 60.16 |
| Support Level | $10.71 | $10.07 |
| Resistance Level | $11.41 | $16.12 |
| Average True Range (ATR) | 0.41 | 0.79 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 51.62 | 62.24 |
DoubleVerify Holdings Inc is a media effectiveness platform that leverages artificial intelligence (AI) to drive superior outcomes for international brands by creating transparent ad transactions. Its solutions provide unbiased data analytics to improve the effectiveness, quality and return on advertising investments. DV Authentic Ad is its proprietary metric measuring whether an ad was delivered in a brand suitable environment, fully viewable, by a real person and in geography, while DV Pinnacle delivers these metrics in real time. The Company's solutions are integrated across programmatic platforms, social media channels and digital publishers, and are accredited by the Media Rating Council for digital ad measurement. It operates in the United States and international markets.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.